The efficacy and safety of raltegravir (RAL) with tenofovir (TDF)/emtricitabine (FTC) have been well studied in human immunodeficiency virus (HIV)-infected patients. However, limited clinical data are available on the use of RAL with abacavir (ABC)/lamivudine (3TC) or zidovudine (ZDV)/3TC. We investigated HIV-1-infected Korean adults, including 13 antiretroviral-naä ƒve patients and 15 antiretroviral-experienced patients, treated with RAL plus ABC/3TC or ZDV/3TC. Virological suppression was achieved in 12 of the 13 (92z) antiretroviral-naä ƒve patients within 24 weeks and in all (100z) patients within 96 weeks. In 13 of the 15 treatment-experienced patients, ritonavir-boosted lopinavir (LPV/r) was replaced with RAL because of hyperlipidemia (n ＝ 11) and diarrhea (n ＝ 2). A significant decrease in median total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels was observed in these patients ( P º 0.01, each). No adverse event related to RAL was observed in any of the 28 patients. The RAL plus ABC/3TC or ZDV/3TC regimens were effective and safe in antiretroviral-naä ƒve Korean HIV-infected patients, and replacing LPV/r with RAL significantly improved lipid abnormalities in patients previously treated with regimens including LPV/r.
SUMMARY:
The efficacy and safety of raltegravir (RAL) with tenofovir (TDF)/emtricitabine (FTC) have been well studied in human immunodeficiency virus (HIV)-infected patients. However, limited clinical data are available on the use of RAL with abacavir (ABC)/lamivudine (3TC) or zidovudine (ZDV)/3TC. We investigated HIV-1-infected Korean adults, including 13 antiretroviral-naä ƒve patients and 15 antiretroviral-experienced patients, treated with RAL plus ABC/3TC or ZDV/3TC. Virological suppression was achieved in 12 of the 13 (92z) antiretroviral-naä ƒve patients within 24 weeks and in all (100z) patients within 96 weeks. In 13 of the 15 treatment-experienced patients, ritonavir-boosted lopinavir (LPV/r) was replaced with RAL because of hyperlipidemia (n ＝ 11) and diarrhea (n ＝ 2). A significant decrease in median total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels was observed in these patients ( P º 0.01, each). No adverse event related to RAL was observed in any of the 28 patients. The RAL plus ABC/3TC or ZDV/3TC regimens were effective and safe in antiretroviral-naä ƒve Korean HIV-infected patients, and replacing LPV/r with RAL significantly improved lipid abnormalities in patients previously treated with regimens including LPV/r. Raltegravir (RAL) has been an important drug in the treatment of HIV infection since 2007 because of its efficacy, small number of toxic effects, and antiretroviral activity against viruses resistant to reverse transcriptase and protease inhibitors (PIs) (1, 2) . RAL, in combination with tenofovir (TDF) and emtricitabine (FTC), was recommended as the initial regimen for antiretroviralnaä ƒve patients (3) based on the results of clinical trials (4-7). However, the efficacy of RAL plus abacavir (ABC)/lamivudine (3TC) or zidovudine (ZDV)/3TC in treatment-naä ƒve patients is not well established, with preliminary data being available from a single clinical trial, which had a limited number of patients (8) . In previous studies, RAL has been shown to have a minimal impact on the serum lipid profile (4-7). Moreover, replacing ritonavir-boosted lopinavir (LPV/r) with RAL was shown to be an effective strategy to reduce the hyperlipidemia associated with PIs (9). However, all these studies used TDF/FTC as a nucleoside reverse transcriptase inhibitor (NRTI) backbone and mainly studied Caucasian populations. Thus, no clinical data are available for Asian patients treated with ABC/3TC, although ABC/3TC is widely used in Asian patients because HLA-5701-related side effects of ABC are very rare in Asians (10) . This study aimed to report the efficacy and safety of RAL plus ABC/3TC or ZDV/3TC regimens in treatment-naä ƒve patients and to evaluate the change in the lipid profile after replacing PIs with RAL in treatment-experienced Korean HIV-1-infected patients.
HIV-1-infected patients treated with RAL plus ABC/3TC or ZDV/3TC regimens at Chonnam National University Hospital (Gwang-ju, Republic of Korea) from August 2010 to December 2012 were investigated. The clinical and laboratory data of the patients were retrospectively reviewed from August 2010 to February 2011, and prospectively collected from March 2011. The study protocol was approved by the institutional review board (IRB No. CNUH-2011-045). CD4-positive T cell counts were determined by flow cytometry using the FACSCalibur cytometer (Becton Dickinson, San Jose, Calif, USA), and HIV-1 RNA was measured using the standard sensitive Roche COBAS } AmpliPrep/ COBAS } TaqMan } HIV-1 Test (version 2.0), which has a detection range of 48-10,000,000 copies/mL. Virological suppression was defined as º48 copies/mL of HIV-1 RNA. Virological rebound was defined as À200 copies/mL of HIV-1 RNA after virological suppression (3). Hypertriglyceridemia and hypercholesterolemia were defined as AE150 mg/dL and AE200 mg/dL, respectively, according to the National Cholesterol Education Program guidelines (11) . Adverse events were considered to be drug related if judged by the investigator as definitely, probably, or possibly related to RAL and graded using the 2004 Division of AIDS toxicity grading scale (12) . The CD4-positive T cell count, HIV-1 viral copies, and lipid levels were compared between baseline and follow-up using the Wilcoxon signed-rank test. All tests of significance were 2tailed, and P values Ã0.05 were deemed to indicate statistical significance. Statistical analyses of the data were performed using the SPSS Statistics software (version 19.0; SPSS Inc., Chicago, Ill., USA).
The initial median plasma HIV-1 RNA burden was patients reported adverse events related to RAL. Among the treatment-experienced patients, LPV/r was replaced with RAL because of hyperlipidemia (n ＝ 11) and diarrhea (n ＝ 2) ( Table 2) . A significant decrease in median total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride levels was observed in these patients ( P º 0.01; Fig. 1 ). Five patients who had been treated with statins because of hyperlipidemia associated with antiretroviral therapy discontinued statin treatment following the replacement of LPV/r with RAL. Efavirenz (EFV) was switched to RAL because of dizziness, insomnia, and somnolence in 2 patients. Among the 15 antiretroviral-experienced patients, 1 (7z) patient experienced loss of virological suppression after LPV/r was replaced with RAL. Two As noted earlier, there has been only a single clinical study of RAL plus ABC/3TC in antiretroviral-naä ƒve HIV-infected patients till date (8) . This study showed a 100z success rate of viral suppression with 96 weeks of therapy in 32 Caucasians, 2 African Americans, and 1 American-Indian. In the present study, we report for the first time that RAL plus ABC/3TC or ZDV/3TC regimens were effective in 13 antiretroviral-naä ƒve Asian patients. Previous studies also showed that replacing LPV/r with RAL was an effective strategy to reduce the hyperlipidemia associated with PIs in Caucasians treated with TDF/FTC as an NRTI backbone (9) . In the present study, we showed that replacing LPV/r with RAL also significantly improved lipid abnormalities in Asian patients treated with ABC/3TC or ZDV/3TC as backbones.
